世界各国のリアルタイムなデータ・インテリジェンスで皆様をお手伝い

Cardiovascular Devices Market Size, Share & Trends Analysis Report By Product (Diagnostic & Monitoring (ECG, Holter, Mobile Cardiac Telemetry), Surgical Devices (Pacemakers, Stents)), By Region, And Segment Forecasts, 2025 - 2033

Cardiovascular Devices Market Size, Share & Trends Analysis Report By Product (Diagnostic & Monitoring (ECG, Holter, Mobile Cardiac Telemetry), Surgical Devices (Pacemakers, Stents)), By Region, And Segment Forecasts, 2025 - 2033


Cardiovascular Devices Market Summary The global cardiovascular devices market size was estimated at USD 53.7 billion in 2024 and is projected to reach USD 106.7 billion by 2033, growing at a C... もっと見る

 

 

出版社 出版年月 電子版価格 納期 ページ数 言語
Grand View Research
グランドビューリサーチ
2025年8月29日 US$5,950
シングルユーザライセンス(印刷不可)
ライセンス・価格情報
注文方法はこちら
電子ファイル - ご注文後3営業日前後 240 英語

 

Summary

Cardiovascular Devices Market Summary

The global cardiovascular devices market size was estimated at USD 53.7 billion in 2024 and is projected to reach USD 106.7 billion by 2033, growing at a CAGR of 7.8% from 2025 to 2033. Cardiovascular disease is one of the most prevalent medical conditions worldwide.

In January 2024, the American Heart Association (AHA) reported that cardiovascular disease (CVD) was the leading cause of death in the U.S., claiming 931,578 lives, surpassing deaths from all cancers and chronic respiratory diseases combined. Therefore, cardiovascular devices are crucial in accurately detecting and mitigating heart disorders, fueling market expansion. The main drivers of this market include rapid technical development, an increase in affordable and effective devices, and rising demand for minimally invasive procedures.

The surge in the number of cases of chronic cardiovascular disorders contributes to the market growth. Increasing cardiovascular disorders have led to an increased demand for cardiovascular devices. Heart or coronary artery stents are among the most essential cardiovascular devices. They facilitate the treatment of cardiac illnesses considered a serious risk to life, namely heart attacks, coronary disease, atrial fibrillation, and the expansion of clogged arteries. In May 2024, the WHO reported that cardiovascular diseases (CVDs) are the top cause of disability and premature death in Europe, accounting for over 42.5% of annual deaths, around 10,000 daily. Men are nearly 2.5 times more likely to die from CVDs than women, with young people (ages 30-69) in Eastern Europe and Central Asia facing a nearly fivefold higher risk compared to their Western European counterparts.

Global Cardiovascular Devices Market Report Segmentation

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global cardiovascular devices market report based on product and region:

• Product Outlook (Revenue, USD Million, 2021 - 2033)
• Diagnostic & Monitoring Devices
• ECG
• Implantable Cardiac Monitors
• Holter Monitors
• Mobile Cardiac Telemetry
• MRI
• Cardiovascular Ultrasound
o 2D
o 3D/4D
o Doppler
• Cardiac Diagnostic Catheters
• PET Scanner
• Surgical Devices
• Cardiac Resynchronization Therapy (CRT)
o CRT-Defibrillator
o CRT-Pacemaker
• Implantable Cardioverter Defibrillators (ICDs)
o Single Chamber ICDs
o Dual Chamber ICDs
• Pacemakers
o Conventional Pacemakers
o Leadless Pacemakers
• Coronary Stents
• Catheters
• Guidewires
• Cannula
• Valves
• Occlusion Devices
• Regional Outlook (Revenue in USD Million, 2021 - 2033)
• North America
• U.S.
• Canada
• Europe
• UK
• Germany
• France
• Italy
• Spain
• Sweden
• Norway
• Denmark
• Asia Pacific
• Japan
• China
• India
• Australia
• Thailand
• South Korea
• Latin America
• Brazil
• Argentina
• Mexico
• Middle East and Africa
• Saudi Arabia
• South Africa
• UAE
• Kuwait

ページTOPに戻る


Table of Contents

Table of Contents

Chapter 1. Methodology and Scope
1.1. Market Segmentation & Scope
1.1.1. Product
1.1.2. Regional scope
1.1.3. Estimates and forecast timeline
1.2. Research Methodology
1.3. Information Procurement
1.3.1. Purchased database
1.3.2. GVR’s internal database
1.3.3. Secondary sources
1.3.4. Primary research
1.3.5. Details of primary research
1.3.5.1. Data for primary interviews in North America
1.3.5.2. Data for primary interviews in Europe
1.3.5.3. Data for primary interviews in Asia Pacific
1.3.5.4. Data for primary interviews in Latin America
1.3.5.5. Data for Primary interviews in MEA
1.4. Information or Data Analysis
1.4.1. Data analysis models
1.5. Market Formulation & Validation
1.6. Model Details
1.6.1. Commodity flow analysis (Model 1)
1.6.2. Approach 1: Commodity flow approach
1.6.3. Volume price analysis (Model 2)
1.6.4. Approach 2: Volume price analysis
1.7. List of Secondary Sources
1.8. List of Primary Sources
1.9. Objectives
Chapter 2. Executive Summary
2.1. Market Outlook
2.2. Segment Outlook
2.2.1. Product outlook
2.2.2. Regional outlook
2.3. Competitive Insights
Chapter 3. Cardiovascular Devices Market Variables, Trends & Scope
3.1. Market Lineage Outlook
3.1.1. Parent market outlook
3.1.2. Related/ancillary market outlook
3.2. Penetration & Growth Prospect Mapping
3.3. Market Dynamics
3.3.1. Market driver analysis
3.3.1.1. Increasing prevalence of cardiovascular diseases
3.3.1.2. Technological advancements
3.3.1.3. Aging population
3.3.2. Market restraint analysis
3.3.2.1. Regulatory challenges
3.3.2.2. High cost of development
3.4. Cardiovascular Devices Market Analysis Tools
3.4.1. Industry Analysis - Porter’s
3.4.1.1. Supplier power
3.4.1.2. Buyer power
3.4.1.3. Substitution threat
3.4.1.4. Threat of new entrant
3.4.1.5. Competitive rivalry
3.4.2. PESTEL Analysis
3.4.2.1. Political landscape
3.4.2.2. Technological landscape
3.4.2.3. Economic landscape
3.4.3. Pipeline Analysis
Chapter 4. Cardiovascular Devices: Product Estimates & Trend Analysis
4.1. Cardiovascular Devices Market: Product Key Takeaways
4.2. Cardiovascular Devices Market: Product Movement & Market Share Analysis, 2024 & 2033
4.3. Diagnostic and Monitoring Devices
4.3.1. Diagnostic and monitoring devices estimates and forecasts, 2021 to 2033 (USD Million)
4.3.1.1. ECG
4.3.1.1.1. ECG market estimates and forecasts, 2021 to 2033 (USD Million)
4.3.1.2. Implantable Cardiac Monitors
4.3.1.2.1. Implantable cardiac monitors market estimates and forecasts, 2021 to 2033 (USD Million)
4.3.1.3. Holter Monitors
4.3.1.3.1. Holter monitors market estimates and forecasts, 2021 to 2033 (USD Million)
4.3.1.4. Mobile Cardiac Telemetry
4.3.1.4.1. Mobile cardiac telemetry market estimates and forecasts, 2021 to 2033 (USD Million)
4.3.1.5. MRI
4.3.1.5.1. MRI estimates and forecasts, 2021 to 2033 (USD Million)
4.3.1.6. Cardiovascular Ultrasound
4.3.1.6.1. Cardiovascular ultrasound market estimates and forecasts, 2021 to 2033 (USD Million)
4.3.1.6.2. 2D
4.3.1.6.2.1. 2D market estimates and forecasts, 2021 to 2033 (USD Million)
4.3.1.6.3. 3D/4D
4.3.1.6.3.1. 3D/4D market estimates and forecasts, 2021 to 2033 (USD Million)
4.3.1.6.4. Doppler
4.3.1.6.4.1. Doppler market estimates and forecasts, 2021 to 2033 (USD Million)
4.3.1.7. Cardiac Diagnostic Catheters
4.3.1.7.1. Cardiac diagnostic catheters market estimates and forecasts, 2021 to 2033 (USD Million)
4.3.1.8. PET Scanner
4.3.1.8.1. PET scanner market estimates and forecasts, 2021 to 2033 (USD Million)
4.4. Surgical Devices
4.4.1. Surgical devices market estimates and forecasts, 2021 to 2033 (USD Million)
4.4.1.1. Cardiac Resynchronization Therapy (CRT)
4.4.1.1.1. Cardiac resynchronization therapy (CRT) market estimates and forecasts, 2021 to 2033 (USD Million)
4.4.1.1.2. CRT-Defibrillator
4.4.1.1.2.1. CRT-defibrillator market estimates and forecasts, 2021 to 2033 (USD Million)
4.4.1.1.3. CRT-Pacemaker
4.4.1.1.3.1. CRT-pacemaker market estimates and forecasts, 2021 to 2033 (USD Million)
4.4.1.2. Implantable Cardioverter Defibrillators (ICDs)
4.4.1.2.1. Implantable cardioverter defibrillators (ICDs) market estimates and forecasts, 2021 to 2033 (USD Million)
4.4.1.2.2. Single Chamber ICDs
4.4.1.2.2.1. Single chamber ICDs market estimates and forecasts, 2021 to 2033 (USD Million)
4.4.1.2.3. Dual Chamber ICDs
4.4.1.2.3.1. Dual chamber ICDs market estimates and forecasts, 2021 to 2033 (USD Million)
4.4.1.3. Pacemakers
4.4.1.3.1. Pacemakers market estimates and forecasts, 2021 to 2033 (USD Million)
4.4.1.3.2. Conventional Pacemakers
4.4.1.3.2.1. Conventional pacemakers market estimates and forecasts, 2021 to 2033 (USD Million)
4.4.1.3.3. Leadless Pacemakers
4.4.1.3.3.1. Leadless pacemakers market estimates and forecasts, 2021 to 2033 (USD Million)
4.4.1.4. Coronary Stents
4.4.1.4.1. Coronary stents market estimates and forecasts, 2021 to 2033 (USD Million)
4.4.1.5. Catheters
4.4.1.5.1. Catheters market estimates and forecasts, 2021 to 2033 (USD Million)
4.4.1.6. Guidewires
4.4.1.6.1. Guidewires market estimates and forecasts, 2021 to 2033 (USD Million)
4.4.1.7. Cannula
4.4.1.7.1. Cannula market estimates and forecasts, 2021 to 2033 (USD Million)
4.4.1.8. Valves
4.4.1.8.1. Valves market estimates and forecasts, 2021 to 2033 (USD Million)
4.4.1.9. Occlusion devices
4.4.1.9.1. Occlusion devices market estimates and forecasts, 2021 to 2033 (USD Million)
Chapter 5. Cardiovascular Devices Market: Regional Estimates & Trend Analysis by Country and Product
5.1. Regional Dashboard
5.2. Market Size, & Forecasts Trend Analysis, 2021 to 2033:
5.3. North America
5.3.1. U.S.
5.3.1.1. Key country dynamics
5.3.1.2. Regulatory framework/ reimbursement structure
5.3.1.3. Competitive scenario
5.3.1.4. U.S. market estimates and forecasts 2021 to 2033 (USD Million)
5.3.2. Canada
5.3.2.1. Key country dynamics
5.3.2.2. Regulatory framework/ reimbursement structure
5.3.2.3. Competitive scenario
5.3.2.4. Canada market estimates and forecasts 2021 to 2033 (USD Million)
5.4. Europe
5.4.1. UK
5.4.1.1. Key country dynamics
5.4.1.2. Regulatory framework/ reimbursement structure
5.4.1.3. Competitive scenario
5.4.1.4. UK market estimates and forecasts 2021 to 2033 (USD Million)
5.4.2. Germany
5.4.2.1. Key country dynamics
5.4.2.2. Regulatory framework/ reimbursement structure
5.4.2.3. Competitive scenario
5.4.2.4. Germany market estimates and forecasts 2021 to 2033 (USD Million)
5.4.3. France
5.4.3.1. Key country dynamics
5.4.3.2. Regulatory framework/ reimbursement structure
5.4.3.3. Competitive scenario
5.4.3.4. France market estimates and forecasts 2021 to 2033 (USD Million)
5.4.4. Italy
5.4.4.1. Key country dynamics
5.4.4.2. Regulatory framework/ reimbursement structure
5.4.4.3. Competitive scenario
5.4.4.4. Italy market estimates and forecasts 2021 to 2033 (USD Million)
5.4.5. Spain
5.4.5.1. Key country dynamics
5.4.5.2. Regulatory framework/ reimbursement structure
5.4.5.3. Competitive scenario
5.4.5.4. Spain market estimates and forecasts 2021 to 2033 (USD Million)
5.4.6. Norway
5.4.6.1. Key country dynamics
5.4.6.2. Regulatory framework/ reimbursement structure
5.4.6.3. Competitive scenario
5.4.6.4. Norway market estimates and forecasts 2021 to 2033 (USD Million)
5.4.7. Sweden
5.4.7.1. Key country dynamics
5.4.7.2. Regulatory framework/ reimbursement structure
5.4.7.3. Competitive scenario
5.4.7.4. Sweden market estimates and forecasts 2021 to 2033 (USD Million)
5.4.8. Denmark
5.4.8.1. Key country dynamics
5.4.8.2. Regulatory framework/ reimbursement structure
5.4.8.3. Competitive scenario
5.4.8.4. Denmark market estimates and forecasts 2021 to 2033 (USD Million)
5.5. Asia Pacific
5.5.1. Japan
5.5.1.1. Key country dynamics
5.5.1.2. Regulatory framework/ reimbursement structure
5.5.1.3. Competitive scenario
5.5.1.4. Japan market estimates and forecasts 2021 to 2033 (USD Million)
5.5.2. China
5.5.2.1. Key country dynamics
5.5.2.2. Regulatory framework/ reimbursement structure
5.5.2.3. Competitive scenario
5.5.2.4. China market estimates and forecasts 2021 to 2033 (USD Million)
5.5.3. India
5.5.3.1. Key country dynamics
5.5.3.2. Regulatory framework/ reimbursement structure
5.5.3.3. Competitive scenario
5.5.3.4. India market estimates and forecasts 2021 to 2033 (USD Million)
5.5.4. Australia
5.5.4.1. Key country dynamics
5.5.4.2. Regulatory framework/ reimbursement structure
5.5.4.3. Competitive scenario
5.5.4.4. Australia market estimates and forecasts 2021 to 2033 (USD Million)
5.5.5. South Korea
5.5.5.1. Key country dynamics
5.5.5.2. Regulatory framework/ reimbursement structure
5.5.5.3. Competitive scenario
5.5.5.4. South Korea market estimates and forecasts 2021 to 2033 (USD Million)
5.5.6. Thailand
5.5.6.1. Key country dynamics
5.5.6.2. Regulatory framework/ reimbursement structure
5.5.6.3. Competitive scenario
5.5.6.4. Thailand market estimates and forecasts 2021 to 2033 (USD Million)
5.6. Latin America
5.6.1. Brazil
5.6.1.1. Key country dynamics
5.6.1.2. Regulatory framework/ reimbursement structure
5.6.1.3. Competitive scenario
5.6.1.4. Brazil market estimates and forecasts 2021 to 2033 (USD Million)
5.6.2. Argentina
5.6.2.1. Key country dynamics
5.6.2.2. Regulatory framework/ reimbursement structure
5.6.2.3. Competitive scenario
5.6.2.4. Argentina market estimates and forecasts 2021 to 2033 (USD Million)
5.6.3. Mexico
5.6.3.1. Key country dynamics
5.6.3.2. Regulatory framework/ reimbursement structure
5.6.3.3. Competitive scenario
5.6.3.4. Mexico market estimates and forecasts 2021 to 2033 (USD Million)
5.7. MEA
5.7.1. South Africa
5.7.1.1. Key country dynamics
5.7.1.2. Regulatory framework/ reimbursement structure
5.7.1.3. Competitive scenario
5.7.1.4. South Africa market estimates and forecasts 2021 to 2033 (USD Million)
5.7.2. Saudi Arabia
5.7.2.1. Key country dynamics
5.7.2.2. Regulatory framework/ reimbursement structure
5.7.2.3. Competitive scenario
5.7.2.4. Saudi Arabia market estimates and forecasts 2021 to 2033 (USD Million)
5.7.3. UAE
5.7.3.1. Key country dynamics
5.7.3.2. Regulatory framework/ reimbursement structure
5.7.3.3. Competitive scenario
5.7.3.4. UAE market estimates and forecasts 2021 to 2033 (USD Million)
5.7.4. Kuwait
5.7.4.1. Key country dynamics
5.7.4.2. Regulatory framework/ reimbursement structure
5.7.4.3. Competitive scenario
5.7.4.4. Kuwait market estimates and forecasts 2021 to 2033 (USD Million)
Chapter 6. Competitive Landscape
6.1. Company/Competition Categorization
6.2. Vendor Landscape
6.2.1. List of key distributors and channel partners
6.2.2. Key customers
6.2.3. Key company market share analysis, 2024
6.3. Market Participant Categorization
6.3.1. Abbott
6.3.1.1. Company overview
6.3.1.2. Financial performance
6.3.1.3. Product benchmarking
6.3.1.4. Strategic initiatives
6.3.2. GE HealthCare
6.3.2.1. Company overview
6.3.2.2. Financial performance
6.3.2.3. Product benchmarking
6.3.2.4. Strategic initiatives
6.3.3. Edwards Lifesciences Corporation
6.3.3.1. Company overview
6.3.3.2. Financial performance
6.3.3.3. Product benchmarking
6.3.3.4. Strategic initiatives
6.3.4. W. L. Gore & Associates, Inc.
6.3.4.1. Company overview
6.3.4.2. Financial performance
6.3.4.3. Product benchmarking
6.3.4.4. Strategic initiatives
6.3.5. Siemens Healthcare GmbH
6.3.5.1. Company overview
6.3.5.2. Financial performance
6.3.5.3. Product benchmarking
6.3.5.4. Strategic initiatives
6.3.6. BIOTRONIK SE & Co. KG
6.3.6.1. Company overview
6.3.6.2. Financial performance
6.3.6.3. Product benchmarking
6.3.6.4. Strategic initiatives
6.3.7. Canon Medical Systems Asia Pte. Ltd.
6.3.7.1. Company overview
6.3.7.2. Financial performance
6.3.7.3. Product benchmarking
6.3.7.4. Strategic initiatives
6.3.8. B. Braun SE
6.3.8.1. Company overview
6.3.8.2. Financial performance
6.3.8.3. Product benchmarking
6.3.8.4. Strategic initiatives
6.3.9. LivaNova PLC
6.3.9.1. Company overview
6.3.9.2. Financial performance
6.3.9.3. Product benchmarking
6.3.9.4. Strategic initiatives
6.3.10. Cardinal Health
6.3.10.1. Company overview
6.3.10.2. Financial performance
6.3.10.3. Product benchmarking
6.3.10.4. Strategic initiatives
6.3.11. Medtronic
6.3.11.1. Company overview
6.3.11.2. Financial performance
6.3.11.3. Product benchmarking
6.3.11.4. Strategic initiatives
6.3.12. Boston Scientific Corporation
6.3.12.1. Company overview
6.3.12.2. Financial performance
6.3.12.3. Product benchmarking
6.3.12.4. Strategic initiatives

 

ページTOPに戻る

ご注文は、お電話またはWEBから承ります。お見積もりの作成もお気軽にご相談ください。

webからのご注文・お問合せはこちらのフォームから承ります

Grand View Research社の 医療機器分野 での最新刊レポート

本レポートと同じKEY WORD(cardiovascular)の最新刊レポート


よくあるご質問


Grand View Research社はどのような調査会社ですか?


グランドビューリサーチ(Grand View Research)は通信技術、化学品、材料、ヘルスケア、エネルギーなど広範な市場を対象にした調査報告書を出版しています。 もっと見る


調査レポートの納品までの日数はどの程度ですか?


在庫のあるものは速納となりますが、平均的には 3-4日と見て下さい。
但し、一部の調査レポートでは、発注を受けた段階で内容更新をして納品をする場合もあります。
発注をする前のお問合せをお願いします。


注文の手続きはどのようになっていますか?


1)お客様からの御問い合わせをいただきます。
2)見積書やサンプルの提示をいたします。
3)お客様指定、もしくは弊社の発注書をメール添付にて発送してください。
4)データリソース社からレポート発行元の調査会社へ納品手配します。
5) 調査会社からお客様へ納品されます。最近は、pdfにてのメール納品が大半です。


お支払方法の方法はどのようになっていますか?


納品と同時にデータリソース社よりお客様へ請求書(必要に応じて納品書も)を発送いたします。
お客様よりデータリソース社へ(通常は円払い)の御振り込みをお願いします。
請求書は、納品日の日付で発行しますので、翌月最終営業日までの当社指定口座への振込みをお願いします。振込み手数料は御社負担にてお願いします。
お客様の御支払い条件が60日以上の場合は御相談ください。
尚、初めてのお取引先や個人の場合、前払いをお願いすることもあります。ご了承のほど、お願いします。


データリソース社はどのような会社ですか?


当社は、世界各国の主要調査会社・レポート出版社と提携し、世界各国の市場調査レポートや技術動向レポートなどを日本国内の企業・公官庁及び教育研究機関に提供しております。
世界各国の「市場・技術・法規制などの」実情を調査・収集される時には、データリソース社にご相談ください。
お客様の御要望にあったデータや情報を抽出する為のレポート紹介や調査のアドバイスも致します。



詳細検索

このレポートへのお問合せ

03-3582-2531

電話お問合せもお気軽に

 

 

2025/10/22 10:26

152.71 円

177.57 円

206.90 円

ページTOPに戻る